Antihyperlipidemic therapies targeting PCSK9

Cardiology in Review

Volumn 22, Issue 3, 2014, Pages 140-146

  Weinreich, Michael ^a   Frishman, William H ^b  

^a Department of Medicine North Shore Long Island Jewish Health System Hofstra University School of Medicine ^*  (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

low density lipoprotein reduction; monoclonal antibodies; proprotein convertase Subtilisin kexin 9 inhibition

Indexed keywords

ALIROCUMAB; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; BOCOCIZUMAB; EVOLOCUMAB; LOW DENSITY LIPOPROTEIN RECEPTOR; PLACEBO; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

DRUG TARGETING; GENE; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 GENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RNA INTERFERENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; HYPERLIPIDEMIAS; TRANSLATIONAL RESEARCH;

ANIMALS; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; PROPROTEIN CONVERTASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERINE ENDOPEPTIDASES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84898597389     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000014     Document Type: Review

References (82)

1. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control [World Health Organization website]. 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241564373- eng.pdf. Accessed January 12, 2013.
2. Health, United States, 2011: With special feature on socioeconomic status health [National Center for Health Statistics website]. 2012. Available at: http://www.cdc.gov/nchs/data/hus/hus11.pdf#071. Accessed January 12, 2013.
3. Wilson P W, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847
4. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
5. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.
6. Wilson P W, Garrison RJ, Castelli W P, et al. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol. 1980;46:649-654.
7. Castelli W P, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835-2838.
8. Gould AL, Davies GM, Alemao E, et al. Cholesterol reduction yields clinical benefts: meta-analysis including recent trials. Clin Ther. 2007;29:778-794.
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) fnal report. Circulation. 2002;106:3143-3421.
10. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther. 2003;1:495-505.
11. Smith SC Jr, Benjamin EJ, Bonow RO, et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458-2473.
12. Stein EA, Ose L, Retterstøl K, et al. Further reduction of low-density lipo-protein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. J Clin Lipidol. 2007;1:280-286
13. The AIM-HIGH Investigators. AIM-HIGH: niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2567.
14. Stone N. Combination therapy: its rationale and the role of ezetimibe. Eur Heart J Suppl. 2002;4:J19-J22.
15. Topol EJ. The diabetes dilemma for statin users [The New York Times website]. March 4, 2012. Available at: http://www.nytimes.com/2012/03/05/ opinion/the-diabetes-dilemma-for-statin-users.html?-&-r=0. Accessed October 23, 2012.
16. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403-414.
17. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163:553-564.
18. Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004;116:408-416.
19. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
20. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556-2564.
21. Jones PH, Davidson MH, Stein EA, et al; STELLAR Study Group. Comparison of the effcacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152-160.
22. Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM. 2004;97:229-235.
23. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.
24. Voora D, Shah SH, Reed CR, et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet. 2008;1:100-106.
25. Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004;291:2821-2827.
26. Frishman WH, Pallerla K. Cardiovascular drugs in development. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 3rd ed. Minneapolis, MN: Cardiotext; 2011:619-630.
27. Lambert G, Sjouke B, Choque B, et al. The PCSK9 decade. J Lipid Res. 2012;53:2515-2524.
28. Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase sub-tilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282:18602-18612.
29. Qian Y W, Schmidt RJ, Zhang Y, et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res. 2007;48:1488-1498.
30. Urban D, Pöss J, Böhm M, et al. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62:1401-1408.
31. Petrides F, Shearston K, Chatelais M, et al. The promises of PCSK9 inhibition. Curr Opin Lipidol. 2013;24:307-312.
32. Goldstein JL, Schrott HG, Hazzard WR, et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544-1568.
33. Innerarity TL, Weisgraber KH, Arnold KS, et al. Familial defective apolipo-protein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA. 1987;84:6919-6923.
34. Abifadel M, Varret M, Rabès J P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156.
35. Maxwell KN, Soccio RE, Duncan EM, et al. Novel putative SREBP and LXR target genes identifed by microarray analysis in liver of cholesterol-fed mice. J Lipid Res. 2003;44:2109-2119.
36. Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004;24:1454-1459.
37. Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res. 2008;49:394-398.
38. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA. 2005;102:2069-2074.
39. Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
40. Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161-165.
41. Berge KE, Ose L, Leren T P. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol. 2006;26:1094-1100.
42. Kotowski IK, Pertsemlidis A, Luke A, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet. 2006;78:410-422.
43. Leren T P. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet. 2004;65:419-422.
44. Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA. 2009;106:9820-9825.
45. Denis M, Marcinkiewicz J, Zaid A, et al. Gene inactivation of proprotein con-vertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation. 2012;125:894-901.
46. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108-1118.
47. McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and effcacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344-2353.
48. Karoui S, Bibani N, Ben Gorbel I, et al. Leukocytoclastic vasculitis: a rare adverse effect secondary to infiximab. Infamm bowel dis. 2011;17:E4E5.
49. Kandula P, Kouides PA. Rituximab-induced leukocytoclastic vasculitis: a case report. Arch Dermatol. 2006;142:246-247.
50. Calabrese LH, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classifcation of hypersensitivity vasculi-tis. Arthritis Rheum. 1990;33:1108-1113.
51. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculi-tides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187-192.
52. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29-36.
53. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891-1900.
54. Stein EA, Swergold GD. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr Atheroscler Rep. 2013;15:310.
55. Dellapena D. PCSK9 inhibitors poised for breakthrough as new cholesterol-lowering therapy. Cardiol Today. 2013;16:1, 13.
56. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercho-lesterolemic subjects on statins. J Am Coll Cardiol. 2012;60:1888-1898.
57. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308:2497-2506.
58. Sullivan D, Olsson A, Scott R, et al: Goal achievement after utilizing an anti-PCSK9 antibody in statin intolerant subjects (GAUSS): interim results from a randomized, double-blind, placebo-controlled study (abstract). Circulation. 2012;126:2782.
59. Giugliano R P, Desai NR, Kohli P, et al; LAPLACE-TIMI 57 Investigators. Effcacy, safety, and tolerability of a monoclonal antibody to proprotein con-vertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007-2017.
60. Kohli P, Desai NR, Giugliano R P, et al. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the effcacy and tol-erability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercho-lesterolemia on background statin therapy. Clin Cardiol. 2012;35:385-391.
61. Desai NR, Kohli P, Giugliano R P, et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, signifcantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation. 2013;128:962-969.
62. Desai NR, Giugliano R P, Zhou J, et al: AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of National Cholesterol Education Program-Adult Treatment Panel III low-density lipoprotein cholesterol goals among high-risk patients. J Am Coll Cardiol. 2014;63:430-33.
63. Koren MJ, Scott R, Kim JB, et al. Effcacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as mono-therapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380:1995-2006.
64. Koren MJ, Scott R, Kim JB, et al. Effcacy and safety of a fully human monoclonal antibody against PCSK9 as monotherapy for hypercholesterolemia: results from the MENDEL study, a global phase 2 trial of AMG 145 (abstract). Circulation. 2012;126:2791.
65. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to pro-protein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408-2417.
66. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to pro-protein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408-2417.
67. Koren MJ, Giugliano R P, Raal FJ, et al for the OSLER investigators: Effcacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterol-emia. 52-week results from the Open-Label Study of Long-term Evaluation Against LDL-C (OSLER) Randomized Trial. Circulation. 2014;129:234-43.
68. Stein EA, Honarpour N, Wasserman SM, et al: Effect of the proprotein con-vertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterol-emia. Circulation. 2013;128:2113-20.
69. US National Institutes of Health. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER). Available at: http://clinicaltrials.gov/ct2/show/NCT01764633/. Accessed November 11, 2013.
70. Gumbiner B, Joh T, Udata C, et al. Effects of 12 weeks of treatment with RN316 (PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects on high and maximal dose statins (abstract). Circulation. 2012;126:2782.
71. Seidah NG, Poirier S, Denis M, et al. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One. 2012;7:e41865.
72. Mayer G, Poirier S, Seidah NG. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem. 2008;283:31791-31801.
73. Cameron J, Ranheim T, Kulseth MA, et al. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis. 2008;201:266-273.
74. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344-1351.
75. Kong WJ, Wei J, Zuo ZY, et al. Combination of simvastatin with berberine improves the lipid-lowering effcacy. Metabolism. 2008;57:1029-1037.
76. Yamamoto T, Harada-Shiba M, Nakatani M, et al. Cholesterol-lowering action of BNA based antisense oligonucleotides targeting PCSK9 in atherogenic diet-induced hypercholesterolemic mice. Mol Ther Nucleic Acids. 2012;1:e22.
77. Lindholm MW, Elmén J, Fisker N, et al. PCSK9 LNA antisense oligonucle-otides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther. 2012;20:376-381.
78. Alnylam Pharmaceuticals. Alnylam reports positive clinical results for ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia. [Alnylam Pharmaceutical Press Release website]. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=148005&p=irol- newsArticle2&ID=1685443&highlight=. Accessed April 14, 2013.
79. Jasmin SB. A putative role for PCSK9 in synaptic remodeling and plasticity in response to brain injury: implications for Alzheimer's disease [McGill University website]. July 2010. Available at: http://digitool.library. mcgill.ca/thesisfle96705.pdf. Accessed October 25, 2012.
80. Postmus I, Trompet S, de Craen AJ, et al. PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardio-vascular clinical events in an elderly population. J Lipid Res. 2013;54:561-566.
81. Sun X, Essalmani R, Day R, et al. Proprotein convertase subtilisin/kexin type 9 defciency reduces melanoma metastasis in liver. Neoplasia. 2012;14:1122-1131.
82. Stein EA: Low-density lipoprotein cholesterol reduction by inhibition of PCSK9. Curr Opin Lipidol. 2013;24:510-17.